1. Home
  2. CNEY vs HCWB Comparison

CNEY vs HCWB Comparison

Compare CNEY & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CN Energy Group Inc.

CNEY

CN Energy Group Inc.

HOLD

Current Price

$0.37

Market Cap

3.4M

Sector

Industrials

ML Signal

HOLD

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$0.28

Market Cap

3.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNEY
HCWB
Founded
2009
2018
Country
China
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
3.7M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
CNEY
HCWB
Price
$0.37
$0.28
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$35.00
AVG Volume (30 Days)
514.2K
21.8M
Earning Date
02-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,099,750.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.25
52 Week High
$3.25
$17.80

Technical Indicators

Market Signals
Indicator
CNEY
HCWB
Relative Strength Index (RSI) 29.06 31.23
Support Level $0.32 N/A
Resistance Level $1.22 $0.78
Average True Range (ATR) 0.07 0.09
MACD -0.01 -0.02
Stochastic Oscillator 7.03 3.42

Price Performance

Historical Comparison
CNEY
HCWB

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Share on Social Networks: